WALTHAM, Mass., Sept. 6, 2024 /PRNewswire/ — Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that on September 1, 2024 the Company granted an inducement award to purchase up to…